Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 19, Issue 9, 2009, Pages 660-666

  Arca, M ^a   Cambuli, V M ^a,b   Montali, A ^a   Sentinelli, F ^b   Filippi, E ^b   Campagna, F ^a   Quagliarini, F ^a   Antonini, R ^a   Romeo, S ^b   Baroni, M G ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Adiponectin; Atorvastatin; FCHL; Fenofibrate; HDL cholesterol

Indexed keywords

ADIPONECTIN; ADIPONECTIN, HUMAN; ANTILIPEMIC AGENT; ATORVASTATIN; BIOLOGICAL MARKER; FENOFIBRATE; HEPTANOIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PYRROLE DERIVATIVE;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD; FAMILIAL HYPERLIPEMIA; FAMILY; FEMALE; GENETICS; HUMAN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PHENOTYPE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADULT; AGE DISTRIBUTION; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; FAMILY; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; INSULIN RESISTANCE; MALE; MIDDLE AGED; PHENOTYPE; PREVALENCE; PROCETOFEN; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 70350575193     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.11.008     Document Type: Article

References (31)

1. Shoulders C.C., Jones E.L., and Naoumova R.P. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet 13 (2004) R149-R160
2. Hopkins P.N., Heiss G., Ellison R.C., Province M.A., Pankow J.S., Eckfeldt J.H., et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 108 (2003) 519-523
3. Ayyobi A.F., McGladdery S.H., McNeely M.J., Austin M.A., Motulsky A.G., and Brunzell J.D. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 23 (2003) 1289-1294
4. Sniderman A.D., Ribalta J., and Castro Cabezas M. How should FCHL be defined and how should we think about its metabolic bases?. Nutr Metab Cardiovasc Dis 11 (2001) 259-273
5. Veerkamp M.J., de Graaf J., Bredie S.J., Hendriks J.C., Demacker P.N., and Stalenhoef A.F. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol 22 (2002) 274-282
6. Veerkamp M.J., de Graaf J., and Stalenhoef A.F. Role of insulin resistance in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 25 (2005) 1026-1031
7. Castro Cabezas M., de Bruin T.W.A., de Valk H.W., Shoulders C.C., Jansen H., and Erkelens D.W. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 92 (1993) 160-168
8. Eurlings P.M., Van Der Kallen C.J., Geurts J.M., Kouwenberg P., Boeckx W.D., and De Bruin T.W. Identification of differentially expressed genes in subcutaneous adipose tissue from subjects with familial combined hyperlipidemia. J Lipid Res 43 (2002) 930-935
9. Aitman T.J., Godsland I.F., Farren B., Crook D., Wong H.J., and Scott J. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 17 (1997) 748-754
10. Karjalainen L., Pihlajamäki J., Karhapää P., and Laakso M. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia?. Arterioscler Thromb Vasc Biol 18 (1998) 1548-1553
11. Pihlajamäki J., Karjalainen L., Karhapää P., Vauhkonen I., and Laakso M. Impaired free fatty acid suppression during hyperinsulinemia is a characteristic finding in familial combined hyperlipidemia, but insulin resistance is observed only in hypertriglyceridemic patients. Arterioscler Thromb Vasc Biol 20 (2000) 164-170
12. Goldstein B.J., and Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89 (2004) 2563-2568
13. Matsuzawa Y., Shimomura I., Kihara S., and Funahashi T. Importance of adipocytokines in obesity-related diseases. Horm Res 60 Suppl. 3 (2003) 56-59
14. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
15. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uccida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP activated protein kinase. Nat Med 8 (2002) 1288-1295
16. Hulthe J., Hultén L.M., and Fagerberg B. Low adipocyte-derived serum protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 52 (2003) 1612-1614
17. Matsubara M., Maruoka S., and Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87 (2002) 2764-2769
18. Chan D.C., Watts G.F., Ng T.W., Uchida Y., Sakai N., Yamashita S., et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem 51 (2005) 578-585
19. Kazumi T., Kawaguchi A., Hirano T., and Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism 53 (2004) 589-593
20. Baratta R., Amato S., Degano C., Farina M.G., Patanè G., Vigneri R., et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89 (2004) 2665-2671
21. van der Vleuten G.M., van Tits L.J., den Heijer M., Lemmers H., Stalenhoef A.F., and de Graaf J. Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile. J Lipid Res 46 (2005) 2398-2404
22. Campagna F., Montali A., Baroni M.G., Antonini T.M., Ricci G., Antonini R., et al. Common variants in the lipoprotein lipase gene, but not those in the insulin receptor substrate-1, the beta3-adrenergic receptor, and the intestinal fatty acid binding protein-2 genes, influence the lipid phenotypic expression in familial combined hyperlipidemia. Metabolism 51 (2002) 1298-1305
23. Arca M., Montali A., Pigna G., Antonini R., Antonini T.M., Petramala L., et al. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hypercholesterolemia. Metabolism 56 (2007) 1534-1541
24. Matthews D.R., Hasker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28 (1985) 412-419
25. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Targher G., et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47 10 (1998) 1643-1649
26. Koh K.K., Han S.H., Quon M.J., Ahn J.Y., and Shin E.K. Metabolic effects of fenofibrate in primary hypertriglyceridemic patients. Diabetes Care 28 (2005) 1419-1424
27. Koh K.K., Quon M.J., Han S.H., Chung W.J., Ahn J.Y., Kim J.A., et al. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care 29 (2006) 195-201
28. Koh K.K., Quon M.J., Han S.H., Chung W.J., Ahn J.Y., Seo Y.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in treatment of combined hyperlipidemia. J Am Coll Cardiol 45 (2005) 1649-1653
29. Koh K.K., Quon M.J., Han S.H., Chung W.J., Ahn J.Y., Seo Y.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110 (2004) 3687-3692
30. ter Avest E., Abbink E.J., de Graaf J., Tack C.J., and Stalenhoef A.F. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest 35 (2005) 558-564
31. Nakamura T., Kodama Y., Takano H., Umetani K., Fujioka D., Saito Y., et al. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis 193 (2007) 449-451